Qiagen N.V. (QGEN) Stock Price, Quote & News

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 31 77 355 6600

Website: www.qiagen.com

Address:

Hulsterweg 82, Venlo, Netherlands

JustB4SnR1se Jan. 8 at 9:14 AM

$QGEN Today's action.

0 · Reply

StockAnalyst_SA Jan. 7 at 12:20 PM

💾 $MU | Memory Goes Structural Full analysis here! It's free👉 @StockAnalyst_SA (No noise !!) 📈 Key info: 10 yrs ago: $16/share | 5x earnings → cyclical (PC & smartphone) Today: $344/share | 9x earnings → AI → structural bottleneck AI demand: data centers, edge, autonomy, agentic systems → huge DRAM & bandwidth needs Jensen Huang: AI models “think longer, retain more context” → memory-first world 💡 Takeaway: AI drives long-term demand → $MU to $500 plausible GLTA / NFA — Not financial advice $PPC $QGEN $BWA $SOFI

0 · Reply

JustB4SnR1se Jan. 6 at 9:03 AM

$QGEN took a starter position yesterday.

0 · Reply

GLPHOTOX Dec. 29 at 12:07 AM

$QGEN so 2026 is almost here, what are your favorite 3 stock pics for 2026 ?

0 · Reply

OfficialStocktwitsUser Dec. 25 at 2:54 AM

$QGEN RSI: 33.40, MACD: -0.1893 Vol: 0.96, MA20: 46.11, MA50: 46.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JarvisFlow Dec. 15 at 9:09 PM

Barclays has adjusted their stance on Qiagen ( $QGEN ), setting the rating to Overweight with a target price of 53 → 55.

0 · Reply

JarvisFlow Dec. 11 at 2:11 PM

Citigroup has adjusted their stance on Qiagen ( $QGEN ), setting the rating to Neutral with a target price of 55 → 50.

0 · Reply

BillionerOfKing Dec. 4 at 12:02 PM

$QGEN Current Stock Price: $46.82 Contracts to trade: $45 QGEN Dec 19 2025 Call Entry: $2.12 Exit: $2.70 ROI: 28% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Src947 Nov. 20 at 5:54 PM

$QGEN people think this is going to be taken out next

0 · Reply

Estimize Nov. 12 at 9:00 PM

Wall St is expecting 0.60 EPS for $QGEN Q4 [Reporting 02/10 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

0 · Reply

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Dec 3, 2025, 6:33 PM EST - 5 weeks ago

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 2:53 PM EST - 5 weeks ago

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 21, 2025, 1:33 PM EST - 7 weeks ago

Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript

Nov 19, 2025, 12:23 PM EST - 7 weeks ago

Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 3:07 PM EST - 7 weeks ago

Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 10, 2025, 1:30 AM EST - 2 months ago

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Nov 6, 2025, 1:49 PM EST - 2 months ago

Seattle's Parse Biosciences to be acquired by Qiagen for $225M

Nov 5, 2025, 3:51 PM EST - 2 months ago

Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 1:04 PM EST - 2 months ago

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

Nov 4, 2025, 1:03 PM EST - 2 months ago

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

Oct 28, 2025, 5:05 PM EDT - 2 months ago

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

Oct 13, 2025, 8:24 AM EDT - 3 months ago

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Sep 25, 2025, 10:57 AM EDT - 3 months ago

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 10, 2025, 4:05 PM EDT - 4 months ago

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Sep 10, 2025, 4:03 PM EDT - 4 months ago

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Sep 9, 2025, 5:01 PM EDT - 4 months ago

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 1:30 AM EDT - 4 months ago

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

Aug 28, 2025, 5:08 PM EDT - 4 months ago

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

Aug 28, 2025, 12:11 PM EDT - 4 months ago

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

Aug 28, 2025, 2:05 AM EDT - 4 months ago

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

Aug 21, 2025, 9:52 AM EDT - 5 months ago

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Aug 6, 2025, 1:44 PM EDT - 5 months ago

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 5 months ago

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

Jul 22, 2025, 4:05 PM EDT - 6 months ago

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

Jul 8, 2025, 5:44 AM EDT - 6 months ago

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

Jun 26, 2025, 1:16 PM EDT - 7 months ago

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

Jun 18, 2025, 4:38 PM EDT - 7 months ago

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

Jun 18, 2025, 4:05 PM EDT - 7 months ago

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

Jun 15, 2025, 4:00 AM EDT - 7 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

INCY

Jun 5, 2025, 6:20 PM EDT - 7 months ago

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

Jun 2, 2025, 2:05 PM EDT - 7 months ago

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Jun 2, 2025, 1:00 PM EDT - 7 months ago

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

May 22, 2025, 4:05 PM EDT - 8 months ago

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 15, 2025, 7:30 AM EDT - 8 months ago

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential

May 12, 2025, 4:05 PM EDT - 8 months ago

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 8, 2025, 2:48 PM EDT - 8 months ago

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:20 PM EDT - 8 months ago

QIAGEN announces plans for transition in leadership of Supervisory Board

May 7, 2025, 4:05 PM EDT - 8 months ago

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 7, 2025, 8:45 AM EDT - 8 months ago

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

May 3, 2025, 10:47 AM EDT - 8 months ago

Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value

Apr 29, 2025, 4:05 PM EDT - 9 months ago

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

Apr 22, 2025, 4:05 PM EDT - 9 months ago

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

Apr 15, 2025, 1:30 AM EDT - 9 months ago

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Apr 8, 2025, 11:22 AM EDT - 9 months ago

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

Apr 6, 2025, 2:28 PM EDT - 9 months ago

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Apr 1, 2025, 1:30 AM EDT - 10 months ago

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Mar 31, 2025, 6:00 AM EDT - 10 months ago

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Mar 6, 2025, 1:00 AM EST - 11 months ago

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

Mar 3, 2025, 1:00 AM EST - 11 months ago

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

JustB4SnR1se Jan. 8 at 9:14 AM

$QGEN Today's action.

0 · Reply

StockAnalyst_SA Jan. 7 at 12:20 PM

0 · Reply

JustB4SnR1se Jan. 6 at 9:03 AM

$QGEN took a starter position yesterday.

0 · Reply

GLPHOTOX Dec. 29 at 12:07 AM

$QGEN so 2026 is almost here, what are your favorite 3 stock pics for 2026 ?

0 · Reply

OfficialStocktwitsUser Dec. 25 at 2:54 AM

0 · Reply

JarvisFlow Dec. 15 at 9:09 PM

Barclays has adjusted their stance on Qiagen ( $QGEN ), setting the rating to Overweight with a target price of 53 → 55.

0 · Reply

JarvisFlow Dec. 11 at 2:11 PM

Citigroup has adjusted their stance on Qiagen ( $QGEN ), setting the rating to Neutral with a target price of 55 → 50.

0 · Reply

BillionerOfKing Dec. 4 at 12:02 PM

0 · Reply

Src947 Nov. 20 at 5:54 PM

$QGEN people think this is going to be taken out next

0 · Reply

Estimize Nov. 12 at 9:00 PM

Wall St is expecting 0.60 EPS for $QGEN Q4 [Reporting 02/10 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

0 · Reply

notreload_ai Nov. 4 at 9:02 PM

$QGEN announces its $225 million acquisition of Parse Biosciences, expanding into scalable single-cell technologies to power AI-driven biological research and drug discovery. https://notreload.xyz/qiagen-acquires-parse-biosciences/

0 · Reply

DonCorleone77 Nov. 4 at 7:07 PM

$QGEN -- Qiagen to acquire Parse Biosciences for up to $280M -- Reports Q3 adjusted EPS 61c, consensus 59c -- Q3 revenue $533M, consensus $525.91M. -- Raises FY25 adjusted EPS target to about $2.38, consensus $2.37.

0 · Reply

OfficialStocktwitsUser Oct. 28 at 4:19 PM

$QGEN RSI: 53.69, MACD: 0.6110 Vol: 0.94, MA20: 47.71, MA50: 47.02 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

vjtweet Oct. 13 at 2:27 AM

$QGEN still bullish. few from my extremely selective list. Small positions - quick profits - tight stops.

0 · Reply

ZacksResearch Sep. 15 at 1:35 PM

$QGEN secures key CE-IVDR certification — will the stock’s momentum continue? 🚀 QIAGEN’s expanded QIAstat-Dx Panel broadens CNS infection coverage with 16 targets, strengthening its Molecular Diagnostics biz. The launch of this enhanced panel is expected in September 2025. With a 5% earnings yield against the industry’s -22.8%, it’s a promising outlook. Discover the potential impact on QGEN here 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-body-12357&ADID=SYND_STOCKTWITS_TWEET_2_2751329_BODY_12357

0 · Reply

ZacksResearch Sep. 15 at 12:35 PM

$QGEN just got a major boost 🚀 The full QIAstat-Dx portfolio is now CE-IVDR certified — strengthening its diagnostics arm and giving the stock a lift. See why this certification could be a game-changer 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-teaser-12355&ADID=SYND_STOCKTWITS_TWEET_2_2751329_TEASER_12355

0 · Reply

nikitatrades Sep. 11 at 1:41 PM

$QGEN CFO: Strong H1 growth (6-7%) outpacing tools sector. Raising FY guidance. Key products QuantiFERON (20+ qtrs double-digit growth) & QIAstat driving performance. New sample prep launches (QIAsymphony Connect) coming. Margin target (31%) likely achieved by '26, ahead of schedule. 🧪 #Qiagen #Investing

0 · Reply

ZacksResearch Sep. 3 at 2:21 PM

$QGEN launches QIAstat-Dx Rise — enhancing diagnostics capabilities! 🚀 The FDA-cleared system offers automated, real-time PCR detection with minimal hands-on time, boosting testing capacity for hospitals and labs. With shares edging up 0.9% post-announcement, this momentum could continue. Discover how QGEN is expanding its diagnostics reach 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-body-10705&ADID=SYND_STOCKTWITS_TWEET_2_2746540_BODY_10705

0 · Reply

ZacksResearch Sep. 3 at 1:20 PM

$QGEN could be gearing up for a catalyst move 🚀 The stock may benefit as the QIAstat-Dx Rise just secured US clearance — a major regulatory milestone. See the full investment angle here 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-teaser-10664&ADID=SYND_STOCKTWITS_TWEET_2_2746540_TEASER_10664

0 · Reply

DonCorleone77 Sep. 2 at 10:23 AM

$QGEN Qiagen announces FDA clearance of QIAstat-Dx Rise

0 · Reply

Estimize Aug. 6 at 8:00 PM

Wall St is expecting 0.58 EPS for $QGEN Q3 [Reporting 11/04 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co

0 · Reply

Market Cap	10.52B
Revenue (ttm)	1.98B
Net Income (ttm)	83.59M
EPS (ttm)	N/A
PE Ratio	19.84
Forward PE	18.92
Profit Margin	4.23%
Debt to Equity Ratio	0.58

Volume	1,276,855
Avg Vol	1,235,482
Day's Range	N/A - N/A
Shares Out	222.29M
Stochastic %K	46%
Beta	0.66
Analysts	Sell
Price Target	$50.82